A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease

This study is a multi-center, randomized, double-blind, placebo-controlled Phase Ⅱ/Ⅲ clinical study to evaluate the efficacy, safety, PK characteristics, PD effects and immunogenicity of CM310 in subjects with moderate to severe Chronic Obstructive Pulmonary Disease（COPD）. The study has two parts. Each part consists of three periods, including an up to 4-week screening period, a 52-week randomized treatment period, and a 8-week safety follow-up period.

NCT Number	NCT06547333
Lead Sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Conditions	Chronic Obstructive Pulmonary Disease
Enrollment	884 participants
Start Date	2024-09-13
Primary Completion	2032-04-29 (estimated)
Study Completion	2032-10-31 (estimated)
Updated on ClinicalTrials.gov	2024-08-14